

Created: March 4, 2020

## **Photodynamic Therapy Laser**

CPT Code 67221, +67225, J3396

All the following must be present before therapy begins:
☐ Choroidal neovascularization membrane (CNVM) secondary to age-related macular degeneration
$\square$ CNVM under the geometric center of the foveal avascular zone
☐ Evidence of classic CNVM on fluorescein angiogram (FA)
$\square$ Area of classic CNVM at least 50% of the area of the total neovascular membrane
$\square$ Retreatment with PDT is reasonable and necessary if, on re-examination, the ophthalmologist finds leakage from classic CNV on the FA
$\square$ Effective for claims with dates of service on and after April 3, 2013 permit either optical coherence tomography (OCT) or FA to assess treatment response.
Effective April 1 2003, PDT may be covered for:
☐ Subfoveal occult with no classic CNV associated with AMD
$\square$ Subfoveal minimally classic CNV (where the area of classic CNV occupies < 50% of the area of the entire lesion) associated with AMD
These two indications are considered reasonable and necessary only when:
$\Box$ The lesions are small (4 disk areas or less in size) at the time of initial treatment or within 3 months prior to initial treatment; and,
$\square$ They have shown evidence of progression with the 3 months prior to initial treatment
Non-covered indications
$\square$ Juxtafoveal or extrafoveal CNV lesions (lesions outside the fovea),
☐ Inability to obtain a FA
☐ Atrophic or "dry" AMD

Procedure note s	should	include
------------------	--------	---------

☐ Diagnosis supporting medical necessity and appropriate indication for use
☐ Relevant diagnostic testing services within the policy guidelines (FA, OCT)
☐ Physician order including, medication name and dosage and signature
☐ Route of administration, site of injection
☐ Dosage in mg and volume in ml
☐ Medication wastage recorded
☐ Consent completed
☐ Physician signature is legible

- Paper chart records have a signature log
- Electronic health records (EHR), the electronic physician signature is secure

## References:

CMS National Coverage Determination, Ocular Photodynamic Therapy (80.2.1) CMS National Coverage Determination, Verteporfin (80.3.1) CMS National Coverage Determination, Photodynamic Therapy (80.2) Academy 2020 Retina Coding: Complete Reference Guide